// App-Quantinova.ai

1009 : Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixekizumab Treated Biological Naïve Patients with Radiographic Axial Spondyloarthritis Achieving Clinically Important Pain at Night Reduction at Week 16: Results from COAST-V Trial

Researchers

Presenter

  • Sofia Ramiro

Principal Investigators

  • Cédric Lukas

  • Michael Nissen

  • Yves Schymura

  • Khai Jing Ng

  • Andrew Bradley

  • Gabriel Doridot

  • Soyi Liu-Leage

  • Antoni Chan

  • James Cheng-Chung WEI

Medical Centers

  • Leiden University Medical Centre, Leiden, Netherlands

  • University Hospital Centre Montpellier, University of Montpellier, Montpellier, France

  • Hopitaux Universitaires de Geneve, Geneva, Switzerland

  • Eli Lilly and Company, Indianapolis, IN

  • Eli Lilly, Neuilly-Sur-Seine, France

  • Royal Berkshire NHS Foundation Trust, Reading, United Kingdom

  • China Medical University Hospital, Taichung, Taiwan

Locations

  • Netherlands

  • France

  • Switzerland

  • United States

  • United Kingdom

  • Taiwan

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • Nutritional risk screening

Drug/Treatment

  • Adalimumab

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02696785

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved